Non-Sterile Compounding Pharmacy Market Research Report By Application (Dermatology, Pediatrics, Pain Management, Hormone Replacement Therapy), By Formulation Type (Topical, Oral, Injection), By End Use (Hospital Pharmacies, Ambulatory Surgical Centers, Home Healthcare) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY
1.1. Market Overview
1.2. Key Findings
1.3. Market Segmentation
1.4. Competitive Landscape
1.5. Challenges and Opportunities
1.6. Future Outlook

2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the study
2.2.1. Research Objective
2.2.2. Assumption
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation

4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value chain Analysis
5.2. Porter's Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis

6. NON-STERILE COMPOUNDING PHARMACY MARKET, BY APPLICATION (USD BILLION)
6.1. Dermatology
6.2. Pediatrics
6.3. Pain Management
6.4. Hormone Replacement Therapy
7. NON-STERILE COMPOUNDING PHARMACY MARKET, BY FORMULATION TYPE (USD BILLION)
7.1. Topical
7.2. Oral
7.3. Injection
8. NON-STERILE COMPOUNDING PHARMACY MARKET, BY END USE (USD BILLION)
8.1. Hospital Pharmacies
8.2. Ambulatory Surgical Centers
8.3. Home Healthcare
9. NON-STERILE COMPOUNDING PHARMACY MARKET, BY REGIONAL (USD BILLION)
9.1. North America
9.1.1. US
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. UK
9.2.3. France
9.2.4. Russia
9.2.5. Italy
9.2.6. Spain
9.2.7. Rest of Europe
9.3. APAC
9.3.1. China
9.3.2. India
9.3.3. Japan
9.3.4. South Korea
9.3.5. Malaysia
9.3.6. Thailand
9.3.7. Indonesia
9.3.8. Rest of APAC
9.4. South America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Argentina
9.4.4. Rest of South America
9.5. MEA
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of MEA

10. COMPETITIVE LANDSCAPE
10.1. Overview
10.2. Competitive Analysis
10.3. Market share Analysis
10.4. Major Growth Strategy in the Non-Sterile Compounding Pharmacy Market
10.5. Competitive Benchmarking
10.6. Leading Players in Terms of Number of Developments in the Non-Sterile Compounding Pharmacy Market
10.7. Key developments and growth strategies
10.7.1. New Product Launch/Service Deployment
10.7.2. Merger & Acquisitions
10.7.3. Joint Ventures
10.8. Major Players Financial Matrix
10.8.1. Sales and Operating Income
10.8.2. Major Players R&D Expenditure. 2023
11. COMPANY PROFILES
11.1. PCCA
11.1.1. Financial Overview
11.1.2. Products Offered
11.1.3. Key Developments
11.1.4. SWOT Analysis
11.1.5. Key Strategies
11.2. PharMEDium Services
11.2.1. Financial Overview
11.2.2. Products Offered
11.2.3. Key Developments
11.2.4. SWOT Analysis
11.2.5. Key Strategies
11.3. Sigma Pharmaceuticals
11.3.1. Financial Overview
11.3.2. Products Offered
11.3.3. Key Developments
11.3.4. SWOT Analysis
11.3.5. Key Strategies
11.4. Cencora
11.4.1. Financial Overview
11.4.2. Products Offered
11.4.3. Key Developments
11.4.4. SWOT Analysis
11.4.5. Key Strategies
11.5. Fagron
11.5.1. Financial Overview
11.5.2. Products Offered
11.5.3. Key Developments
11.5.4. SWOT Analysis
11.5.5. Key Strategies
11.6. Walgreens Boots Alliance
11.6.1. Financial Overview
11.6.2. Products Offered
11.6.3. Key Developments
11.6.4. SWOT Analysis
11.6.5. Key Strategies
11.7. Renaissance Pharmacy
11.7.1. Financial Overview
11.7.2. Products Offered
11.7.3. Key Developments
11.7.4. SWOT Analysis
11.7.5. Key Strategies
11.8. Cardinal Health
11.8.1. Financial Overview
11.8.2. Products Offered
11.8.3. Key Developments
11.8.4. SWOT Analysis
11.8.5. Key Strategies
11.9. Eli Lilly and Company
11.9.1. Financial Overview
11.9.2. Products Offered
11.9.3. Key Developments
11.9.4. SWOT Analysis
11.9.5. Key Strategies
11.10. Compounded Solutions
11.10.1. Financial Overview
11.10.2. Products Offered
11.10.3. Key Developments
11.10.4. SWOT Analysis
11.10.5. Key Strategies
11.11. BioCare Copenhagen
11.11.1. Financial Overview
11.11.2. Products Offered
11.11.3. Key Developments
11.11.4. SWOT Analysis
11.11.5. Key Strategies
11.12. Kroger Pharmacy
11.12.1. Financial Overview
11.12.2. Products Offered
11.12.3. Key Developments
11.12.4. SWOT Analysis
11.12.5. Key Strategies
11.13. Parkdale Pharmacy
11.13.1. Financial Overview
11.13.2. Products Offered
11.13.3. Key Developments
11.13.4. SWOT Analysis
11.13.5. Key Strategies
11.14. Avella Pharmacy
11.14.1. Financial Overview
11.14.2. Products Offered
11.14.3. Key Developments
11.14.4. SWOT Analysis
11.14.5. Key Strategies
12. APPENDIX
12.1. References
12.2. Related Reports
LIST OF TABLES

TABLE 1. LIST OF ASSUMPTIONS
TABLE 2. NORTH AMERICA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
TABLE 3. NORTH AMERICA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 4. NORTH AMERICA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
TABLE 5. NORTH AMERICA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 6. US NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
TABLE 7. US NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 8. US NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
TABLE 9. US NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 10. CANADA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
TABLE 11. CANADA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 12. CANADA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
TABLE 13. CANADA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 14. EUROPE NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
TABLE 15. EUROPE NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 16. EUROPE NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
TABLE 17. EUROPE NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 18. GERMANY NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
TABLE 19. GERMANY NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 20. GERMANY NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
TABLE 21. GERMANY NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 22. UK NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
TABLE 23. UK NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 24. UK NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
TABLE 25. UK NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 26. FRANCE NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
TABLE 27. FRANCE NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 28. FRANCE NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
TABLE 29. FRANCE NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 30. RUSSIA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
TABLE 31. RUSSIA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 32. RUSSIA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
TABLE 33. RUSSIA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 34. ITALY NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
TABLE 35. ITALY NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 36. ITALY NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
TABLE 37. ITALY NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 38. SPAIN NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
TABLE 39. SPAIN NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 40. SPAIN NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
TABLE 41. SPAIN NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 42. REST OF EUROPE NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
TABLE 43. REST OF EUROPE NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 44. REST OF EUROPE NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
TABLE 45. REST OF EUROPE NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 46. APAC NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
TABLE 47. APAC NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 48. APAC NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
TABLE 49. APAC NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 50. CHINA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
TABLE 51. CHINA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 52. CHINA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
TABLE 53. CHINA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 54. INDIA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
TABLE 55. INDIA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 56. INDIA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
TABLE 57. INDIA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 58. JAPAN NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
TABLE 59. JAPAN NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 60. JAPAN NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
TABLE 61. JAPAN NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 62. SOUTH KOREA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
TABLE 63. SOUTH KOREA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 64. SOUTH KOREA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
TABLE 65. SOUTH KOREA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 66. MALAYSIA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
TABLE 67. MALAYSIA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 68. MALAYSIA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
TABLE 69. MALAYSIA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 70. THAILAND NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
TABLE 71. THAILAND NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 72. THAILAND NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
TABLE 73. THAILAND NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 74. INDONESIA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
TABLE 75. INDONESIA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 76. INDONESIA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
TABLE 77. INDONESIA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 78. REST OF APAC NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
TABLE 79. REST OF APAC NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 80. REST OF APAC NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
TABLE 81. REST OF APAC NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 82. SOUTH AMERICA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
TABLE 83. SOUTH AMERICA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 84. SOUTH AMERICA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
TABLE 85. SOUTH AMERICA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 86. BRAZIL NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
TABLE 87. BRAZIL NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 88. BRAZIL NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
TABLE 89. BRAZIL NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 90. MEXICO NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
TABLE 91. MEXICO NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 92. MEXICO NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
TABLE 93. MEXICO NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 94. ARGENTINA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
TABLE 95. ARGENTINA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 96. ARGENTINA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
TABLE 97. ARGENTINA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 98. REST OF SOUTH AMERICA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
TABLE 99. REST OF SOUTH AMERICA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 100. REST OF SOUTH AMERICA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
TABLE 101. REST OF SOUTH AMERICA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 102. MEA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
TABLE 103. MEA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 104. MEA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
TABLE 105. MEA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 106. GCC COUNTRIES NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
TABLE 107. GCC COUNTRIES NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 108. GCC COUNTRIES NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
TABLE 109. GCC COUNTRIES NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 110. SOUTH AFRICA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
TABLE 111. SOUTH AFRICA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 112. SOUTH AFRICA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
TABLE 113. SOUTH AFRICA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 114. REST OF MEA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD BILLIONS)
TABLE 115. REST OF MEA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY FORMULATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 116. REST OF MEA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD BILLIONS)
TABLE 117. REST OF MEA NON-STERILE COMPOUNDING PHARMACY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 118. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
TABLE 119. ACQUISITION/PARTNERSHIP

LIST OF FIGURES

FIGURE 1. MARKET SYNOPSIS
FIGURE 2. NORTH AMERICA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS
FIGURE 3. US NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY APPLICATION
FIGURE 4. US NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY FORMULATION TYPE
FIGURE 5. US NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY END USE
FIGURE 6. US NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY REGIONAL
FIGURE 7. CANADA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY APPLICATION
FIGURE 8. CANADA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY FORMULATION TYPE
FIGURE 9. CANADA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY END USE
FIGURE 10. CANADA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY REGIONAL
FIGURE 11. EUROPE NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS
FIGURE 12. GERMANY NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY APPLICATION
FIGURE 13. GERMANY NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY FORMULATION TYPE
FIGURE 14. GERMANY NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY END USE
FIGURE 15. GERMANY NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY REGIONAL
FIGURE 16. UK NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY APPLICATION
FIGURE 17. UK NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY FORMULATION TYPE
FIGURE 18. UK NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY END USE
FIGURE 19. UK NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY REGIONAL
FIGURE 20. FRANCE NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY APPLICATION
FIGURE 21. FRANCE NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY FORMULATION TYPE
FIGURE 22. FRANCE NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY END USE
FIGURE 23. FRANCE NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY REGIONAL
FIGURE 24. RUSSIA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY APPLICATION
FIGURE 25. RUSSIA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY FORMULATION TYPE
FIGURE 26. RUSSIA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY END USE
FIGURE 27. RUSSIA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY REGIONAL
FIGURE 28. ITALY NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY APPLICATION
FIGURE 29. ITALY NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY FORMULATION TYPE
FIGURE 30. ITALY NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY END USE
FIGURE 31. ITALY NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY REGIONAL
FIGURE 32. SPAIN NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY APPLICATION
FIGURE 33. SPAIN NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY FORMULATION TYPE
FIGURE 34. SPAIN NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY END USE
FIGURE 35. SPAIN NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY REGIONAL
FIGURE 36. REST OF EUROPE NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY APPLICATION
FIGURE 37. REST OF EUROPE NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY FORMULATION TYPE
FIGURE 38. REST OF EUROPE NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY END USE
FIGURE 39. REST OF EUROPE NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY REGIONAL
FIGURE 40. APAC NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS
FIGURE 41. CHINA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY APPLICATION
FIGURE 42. CHINA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY FORMULATION TYPE
FIGURE 43. CHINA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY END USE
FIGURE 44. CHINA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY REGIONAL
FIGURE 45. INDIA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY APPLICATION
FIGURE 46. INDIA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY FORMULATION TYPE
FIGURE 47. INDIA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY END USE
FIGURE 48. INDIA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY REGIONAL
FIGURE 49. JAPAN NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY APPLICATION
FIGURE 50. JAPAN NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY FORMULATION TYPE
FIGURE 51. JAPAN NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY END USE
FIGURE 52. JAPAN NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY REGIONAL
FIGURE 53. SOUTH KOREA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY APPLICATION
FIGURE 54. SOUTH KOREA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY FORMULATION TYPE
FIGURE 55. SOUTH KOREA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY END USE
FIGURE 56. SOUTH KOREA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY REGIONAL
FIGURE 57. MALAYSIA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY APPLICATION
FIGURE 58. MALAYSIA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY FORMULATION TYPE
FIGURE 59. MALAYSIA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY END USE
FIGURE 60. MALAYSIA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY REGIONAL
FIGURE 61. THAILAND NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY APPLICATION
FIGURE 62. THAILAND NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY FORMULATION TYPE
FIGURE 63. THAILAND NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY END USE
FIGURE 64. THAILAND NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY REGIONAL
FIGURE 65. INDONESIA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY APPLICATION
FIGURE 66. INDONESIA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY FORMULATION TYPE
FIGURE 67. INDONESIA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY END USE
FIGURE 68. INDONESIA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY REGIONAL
FIGURE 69. REST OF APAC NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY APPLICATION
FIGURE 70. REST OF APAC NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY FORMULATION TYPE
FIGURE 71. REST OF APAC NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY END USE
FIGURE 72. REST OF APAC NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY REGIONAL
FIGURE 73. SOUTH AMERICA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS
FIGURE 74. BRAZIL NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY APPLICATION
FIGURE 75. BRAZIL NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY FORMULATION TYPE
FIGURE 76. BRAZIL NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY END USE
FIGURE 77. BRAZIL NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY REGIONAL
FIGURE 78. MEXICO NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY APPLICATION
FIGURE 79. MEXICO NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY FORMULATION TYPE
FIGURE 80. MEXICO NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY END USE
FIGURE 81. MEXICO NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY REGIONAL
FIGURE 82. ARGENTINA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY APPLICATION
FIGURE 83. ARGENTINA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY FORMULATION TYPE
FIGURE 84. ARGENTINA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY END USE
FIGURE 85. ARGENTINA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY REGIONAL
FIGURE 86. REST OF SOUTH AMERICA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY APPLICATION
FIGURE 87. REST OF SOUTH AMERICA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY FORMULATION TYPE
FIGURE 88. REST OF SOUTH AMERICA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY END USE
FIGURE 89. REST OF SOUTH AMERICA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY REGIONAL
FIGURE 90. MEA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS
FIGURE 91. GCC COUNTRIES NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY APPLICATION
FIGURE 92. GCC COUNTRIES NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY FORMULATION TYPE
FIGURE 93. GCC COUNTRIES NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY END USE
FIGURE 94. GCC COUNTRIES NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY REGIONAL
FIGURE 95. SOUTH AFRICA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY APPLICATION
FIGURE 96. SOUTH AFRICA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY FORMULATION TYPE
FIGURE 97. SOUTH AFRICA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY END USE
FIGURE 98. SOUTH AFRICA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY REGIONAL
FIGURE 99. REST OF MEA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY APPLICATION
FIGURE 100. REST OF MEA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY FORMULATION TYPE
FIGURE 101. REST OF MEA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY END USE
FIGURE 102. REST OF MEA NON-STERILE COMPOUNDING PHARMACY MARKET ANALYSIS BY REGIONAL
FIGURE 103. KEY BUYING CRITERIA OF NON-STERILE COMPOUNDING PHARMACY MARKET
FIGURE 104. RESEARCH PROCESS OF MRFR
FIGURE 105. DRO ANALYSIS OF NON-STERILE COMPOUNDING PHARMACY MARKET
FIGURE 106. DRIVERS IMPACT ANALYSIS: NON-STERILE COMPOUNDING PHARMACY MARKET
FIGURE 107. RESTRAINTS IMPACT ANALYSIS: NON-STERILE COMPOUNDING PHARMACY MARKET
FIGURE 108. SUPPLY / VALUE CHAIN: NON-STERILE COMPOUNDING PHARMACY MARKET
FIGURE 109. NON-STERILE COMPOUNDING PHARMACY MARKET, BY APPLICATION, 2025 (% SHARE)
FIGURE 110. NON-STERILE COMPOUNDING PHARMACY MARKET, BY APPLICATION, 2019 TO 2035 (USD Billions)
FIGURE 111. NON-STERILE COMPOUNDING PHARMACY MARKET, BY FORMULATION TYPE, 2025 (% SHARE)
FIGURE 112. NON-STERILE COMPOUNDING PHARMACY MARKET, BY FORMULATION TYPE, 2019 TO 2035 (USD Billions)
FIGURE 113. NON-STERILE COMPOUNDING PHARMACY MARKET, BY END USE, 2025 (% SHARE)
FIGURE 114. NON-STERILE COMPOUNDING PHARMACY MARKET, BY END USE, 2019 TO 2035 (USD Billions)
FIGURE 115. NON-STERILE COMPOUNDING PHARMACY MARKET, BY REGIONAL, 2025 (% SHARE)
FIGURE 116. NON-STERILE COMPOUNDING PHARMACY MARKET, BY REGIONAL, 2019 TO 2035 (USD Billions)
FIGURE 117. BENCHMARKING OF MAJOR COMPETITORS